|
| |
SIGA TechnologiesSIGA Technologies is applying bacterial genomics in the design and development of novel products for the prevention and treatment of serious infectious diseases. With broad technology platforms in both vaccines and antibiotics, SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria.
SIGA's lead product programs focus on:
Mucosal vaccines against strep throat and sexually transmitted diseases
Commensal bacteria for the delivery of vaccines and protein therapeutics
Novel antibiotics against Gram-positive and Gram-negative bacteria
Surface Protein Expression System for the cost-effective production of proteins
SIGA's vaccine and antibiotic platforms are based on its pioneering research into the structure, function and processing of bacterial surface proteins. SIGA is leveraging these platforms through multiple strategic partners, including Wyeth-Ayerst Laboratories (the pharmaceutical division of American Home Products), and the National Institutes of Health.
| Contact Details: |
| 420 Lexington Avenue, Suite 408 |
| New York |
| New York |
| 10170 |
| United States of America |
| Tel: | (212) 672-9100 |
| Fax: | (212) 697-3130 |
| Email: | info@siga.com |
| WWW: | www.siga.com/
|
|
Loading...
|
Recent Publications by SIGA Technologies: |  |
ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation.
Orthopoxvirus infections, such as smallpox, can lead to severe systemic... | 16th September, 2009
| SIGA Technologies, Inc., 4575 SW Research Way, Suite 230, Corvallis, OR
| Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. Epub 2009 Sep 14.
DOI Direct Link |
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Therapeutics for the treatment of pathogenic orthopoxvirus infections are... | 25th June, 2009
| SIGA Technologies, Inc., 4575 SW Research Way, Suite 230, Corvallis, OR
| Antimicrob Agents Chemother. 2009 May;53(5):1817-22. Epub 2009 Feb 17.
DOI Direct Link |
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis.
BACKGROUND: Proteins associated with the late endosome (LE) appear to play... | 13th June, 2009
| SIGA Technologies
| Virol J. 2009 Apr 28;6:44.
DOI Direct Link |
Identification of a broad-spectrum arenavirus entry inhibitor.
Several arenaviruses, including Lassa virus (LASV), are causative agents... | 1st November, 2008
| SIGA Technologies, Inc., Corvallis, Oregon 97333, USA.
| J Virol. 2008 Nov;82(21):10768-75. Epub 2008 Aug 20.
DOI Direct Link |
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
ST-246 is a novel, potent orthopoxvirus egress inhibitor that is being... | 14th August, 2008
| SIGA Technologies, Inc., 4575 SW Research Way, Corvallis, OR 97330, USA.
| Antimicrob Agents Chemother. 2008 May;52(5):1721-7. Epub 2008 Mar 3.
DOI Direct Link |
→View more SIGA Technologies research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 439 times since April 2007, the link to the organisation's website has been followed 99 times Recent Search Terms used to find this page: america postcode 97333 | siga technologies negatives | . Search for more companies in New York Search for more companies in New York This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for SIGA Technologies |
